Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. 

Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.

Invus

OrbiMed

RA Capital Management

Convergent Therapeutics, Inc.

Learn more about our technology and how we are using #antibodies as a targeted therapy for delivering a #radioactive payload to #cancer cells.  Check out this video below! 
#radiotherapeutics 

Today, we announced that the U.S. Food and Drug Administration ("FDA") has cleared the investigational new drug ("IND") application for CONV01-α, our lead candidate for the treatment of patients with advanced prostate cancer.
 
“While we have already treated well over 100 advanced prostate cancer patients in the context of investigator INDs, this new IND will allow us to rapidly advance CONV01-α into Phase 3 studies and expand the scope of clinical development of CONV01-α as a monotherapy and in combination with other cancer therapies,” said Convergent’s Co-founder and CEO, Philip Kantoff, MD.
 
We are on track to conduct Phase 2 clinical trials in 2024 preparing for a registrational program in 2025. 
 
To learn more about CONV01-α and read the full announcement, visit: https://lnkd.in/esyxbsfb
 
#ProstateCancer #Oncology

Today, the American Society of Clinical Oncology (ASCO) announced that Convergent Co-Founder and CEO Dr. Philip Kantoff has been awarded the Excellence in Teaching Award. This award recognizes teaching as a vital part of #cancer care for the population and underscores ASCO’s belief that teaching is as important to the future of cancer medicine as are research, care delivery and clinical work.
 
We are proud of the work Dr. Kantoff has done throughout his career to advance cancer treatment, including his dedication to mentorship of residents, clinical and post-doctoral fellows, and trainees.
 
Dr. Kantoff will be honored at the upcoming ASCO Annual Meeting in Chicago. For more on the award, visit https://lnkd.in/eG7KK3SE #ASCO2024 #ProstateCancer #Oncology

This morning, Convergent announced the appointment of Scott Myers as Chairman of our Board of Directors. "Scott brings an enormous amount of experience and expertise as both a Chief Executive Officer as well as a board member and chair in numerous life science companies," says Dr. Philip Kantoff, Co-Founder and CEO of Convergent. 

Read more here: https://lnkd.in/eYH-cvTQ

Our team is heading to San Francisco for the 42nd Annual J.P. Morgan Healthcare Conference and will be sharing more about our exciting targeted radiotherapy. We look forward to hearing expert insights on trends shaping the industry now, and in the year ahead. We can’t wait to see everyone there! 

#JPM24 #radiopharmaceuticals #prostatecancer

Convergent Rx is a company that appears to specialize in healthcare services, potentially offering solutions in medication management, pharmacy services, or healthcare technology. The exact nature of their services is not specified in the provided context, but their privacy policy suggests they handle personal health information, which is common in the healthcare industry.

COM:CONVERGENTRX

Convergent Rx

Filings Not Available